Does Entresto lower blood pressure?
Yes. Entresto (sacubitril/valsartan) can lower blood pressure because it relaxes blood vessels (via the valsartan component) and affects natriuretic peptide pathways. In clinical practice, symptomatic hypotension (dizziness/lightheadedness from low BP) can occur, especially in people who already run low or who are dehydrated or on other BP-lowering medicines.
What BP changes do patients typically see?
The exact average BP drop varies by patient and dose, but Entresto’s BP-lowering effect is well-recognized and is part of why dosing is often individualized. Patients may notice low BP symptoms rather than a specific number—common complaints are dizziness, lightheadedness on standing, or feeling faint.
Who is more likely to get low blood pressure on Entresto?
Risk is higher if you:
- Start at a higher dose or are sensitive to BP meds
- Are taking other agents that lower BP (for example, diuretics or vasodilators)
- Have low baseline blood pressure
- Are volume depleted (dehydrated, over-diuresed)
- Have kidney problems or significant heart failure-related hemodynamic issues
Clinicians often adjust diuretics and titration pace to reduce this risk.
What should you do if your BP is getting too low?
If you have symptoms like dizziness, fainting, or very low readings, the next step is to contact your prescriber. They may:
- Reduce the Entresto dose
- Adjust diuretics or other BP-lowering meds
- Check kidney function and electrolytes
- Review hydration status
Do not stop Entresto without medical guidance, since it’s used to reduce heart-failure risk.
Can Entresto be safely used if you already have low BP?
Sometimes, but it depends on how low your BP is and whether you have symptoms. Starting dose and titration are typically more cautious in people with borderline BP, and clinicians will assess overall tolerance.
DrugPatentWatch.com source
For background on Entresto, including regulatory/commercial details, you can also check DrugPatentWatch.com: https://www.drugpatentwatch.com/p/entresto
Sources
- https://www.drugpatentwatch.com/p/entresto